Clinical trials: Semaglutide, completed
Type 2 Diabetes, Obesity
The Separate and Combined Effects of Long-term GIP and GLP-1 Receptor Activation in Patients with Type 2 Diabetes
Due to reports of a severely reduced insulinotropic effect of the incretin hormone glucose-dependent insulinotropic polypeptide (GIP) in type 2 diabetes (T2D), GIP has not been considered therapeutically viable in T2D.
- Trial name
- NCT05078255
- Testing
- Semaglutide 1.34 MG/ML [Ozempic], Glucose-dependent insulinotropic polypeptide (GIP)
- Where
- Denmark
- Volunteers
- 61 people
- Sponsor
- Asger Lund, MD
Diabetes Mellitus, Type 2
A Research Study to See How Much Semaglutide and SNAC is in the Milk of Healthy, Breastfeeding Women Taking Semaglutide Tablets
Participants in the study, will receive the study drug once daily for 10 days in tablet form for oral (by mouth) intake. On day 1 to 5 the tablet will contain 3 mg semaglutide, and on day 6-10 the tablet will contain 7 mg…
- Trial name
- NCT04817644
- Testing
- Oral semaglutide
- Where
- 2 sites in United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Stroke, Stroke, Acute
Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion Therapies
Endovascular thrombectomy (EVT) is a highly effective therapy for acute ischemic stroke with large vessel occlusion (LVO). EVT was proven efficacious in selected patients with symptoms onset or last-known-well time of up to 24…
- Conditions
- Stroke, Stroke, Acute, Stroke, Ischemic, Brain Diseases
- Trial name
- GALLOP (NCT05920889)
- Testing
- Semaglutide
- Where
- 2 sites in China, Hong Kong
- Volunteers
- 140 people
- Sponsor
- Chinese University of Hong Kong
Type 2 Diabetes
Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D
This study is designed to determine whether therapy with once-weekly sc semaglutide in combination with once-daily insulin degludec will be capable of maintaining (or improving) glycemic control, when substituted for multiple…
- Trial name
- TRANSITION-T2D (NCT04538352)
- Testing
- Semaglutide, Insulin Degludec, Insulin aspart
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- The Cleveland Clinic
Obesity and Obesity-related Medical Conditions
Sleeve Gastrectomy vs. Lifestyle & Medications: Impact on BMI Trajectory and Target Attainment in a Matched Cohort Study
Obesity is a widespread and preventable condition affecting over a billion people globally, with rates expected to rise significantly by 2030.
- Trial name
- NCT06820047
- Testing
- Laparoscopic sleeve gastrectomy, Obesity pharmacotherapy
- Where
- 2 sites in Italy
- Volunteers
- 190 people
- Sponsor
- University of Roma La Sapienza
Healthy, Obesity
A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906
This study is open to adults between 18 and 55 years of age who are living with overweight or obesity. People with a body mass index (BMI) from 27 to 40 kg/m2 can join the study.
- Trial name
- NCT05751226
- Testing
- BI 1820237, semaglutide, BI 456906
- Where
- Germany
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus, Chronic Kidney Diseases
A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus
A Phase 2b, study to measure the effect of Cotadutide at different doses versus placebo or comparator (semaglutide) in participants who have Chronic Kidney Disease with Type 2 Diabetes Mellitus.
- Trial name
- NCT04515849
- Testing
- Cotadutide 100 micrograms, Cotadutide 300 micrograms, Cotadutide 600 micrograms
- Where
- 83 sites in Australia, Canada and 6 more
- Volunteers
- 248 people
- Sponsor
- AstraZeneca
Diabetes Mellitus Type 2, Iron Absorption
Semaglutide and Intestinal Iron Absorption
Semaglutide belongs to a group of long-acting glucagon-like peptide 1 receptor agonists (GLP-1). Disorders in iron absorption have been linked to numerous medication, dietary, and nutrient interactions thus far.
- Trial name
- NCT06629688
- Testing
- semaglutide
- Where
- Croatia
- Volunteers
- 51 people
- Sponsor
- University Hospital Dubrava
Healthy
A Study of Enlicitide Decanoate (MK-0616) and Semaglutide in Healthy Adult Participants (MK-0616-023)
The goal of this study is to learn what happens in a person's body over time when they take enlicitide decanoate and semaglutide alone or at the same time.
- Trial name
- NCT06699329
- Testing
- Enlicitide Decanoate, Semaglutide
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
A Research Study to Look at How Insulin 287 and Semaglutide Work in the Body of People With Type 2 Diabetes When Taken Alone or Together
The study will look at how insulin 287 and semaglutide work in the body, both when given alone or together. This study will look at the way insulin 287 and semaglutide reach and stay in participants' blood after injection when…
- Trial name
- NCT03789578
- Testing
- NNC0148-0287sema, Semaglutide, NNC0148-0287
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Novo Nordisk A/S
Obesity, Obesity; Drug
Latino Semaglutide Study
The purpose of this study to understand better how this anti-obesity medication works to assist individuals to lose weight and maintain weight loss.
- Conditions
- Obesity, Obesity; Drug, Overweight or Obesity, Weight Loss
- Trial name
- LSS (NCT05087342)
- Testing
- Semaglutide 2.4mg
- Where
- United States
- Volunteers
- 119 people
- Sponsor
- Loma Linda University
Diabetes Mellitus, Type 2, Healthy Participants
A Research Trial Looking at the Comparability of 2 Different Concentrations of Semaglutide for the 0.5 Milligram (mg) Dose
In this study, a known investigational medicine called 'semaglutide' will be tested in 2 drug concentrations of 0.68 milligram per milliliter (mg/mL) and 1.34 mg/mL.
- Trial name
- NCT05689099
- Testing
- Semaglutide B, 1.34 mg/mL, Semaglutide B, 0.68 mg/mL
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes
This study compares 2 medicines for type 2 diabetes: oral semaglutide (a new medicine) and sitagliptin (a medicine doctors can already prescribe).
- Trial name
- PIONEER 12 (NCT04017832)
- Testing
- Oral semaglutide, Sitagliptin
- Where
- 93 sites in Algeria, Brazil and 7 more
- Volunteers
- 1,441 people
- Sponsor
- Novo Nordisk A/S
HIV Infections, Non-Alcoholic Fatty Liver Disease
Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)
The purpose of this study was to evaluate the effects of semaglutide on intra-hepatic triglyceride (IHTG) content in people living with HIV (PLWH), central adiposity, insulin resistance or pre-diabetes, and hepatic steatosis.
- Trial name
- NCT04216589
- Testing
- Semaglutide
- Where
- 9 sites in United States, Brazil
- Volunteers
- 51 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Diabetes Mellitus, Type 2
Prediction of the SEPRA Diabetes Trial in Healthcare Claims Data
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials.
- Trial name
- NCT05577728
- Testing
- New use of semaglutide injection, New initiation of "standard of care" (SGL2i, 2nd generation SU, DPP-4i and GLP-1 RA except for semaglutide inj or oral)
- Where
- United States
- Volunteers
- 2,316 people
- Sponsor
- Brigham and Women's Hospital
Diabetes Mellitus, Type 2
A Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 Diabetes
The study compares 2 medicines for type 2 diabetes: oral semaglutide (a new medicine) and placebo (a dummy medicine). Researchers will test semaglutide to see how well it works compared to placebo.
- Trial name
- PIONEER 11 (NCT04109547)
- Testing
- Oral semaglutide
- Where
- 66 sites in Algeria, China and 4 more
- Volunteers
- 521 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice
The purpose of the study is to collect information on how Rybelsus® works in people with type 2 diabetes and to see if Rybelsus® can lower their blood sugar levels.
- Trial name
- PIONEER REAL (NCT04537624)
- Testing
- Oral Semaglutide
- Where
- Switzerland
- Volunteers
- 194 people
- Sponsor
- Novo Nordisk A/S
Healthy Volunteers, Type 2 Diabetes
A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy People
The aim of this study is to investigate the amount of the active ingredient and helping agent in the blood in two different tablet versions of Semaglutide.
- Trial name
- NCT05227196
- Testing
- Semaglutide D Dose 1, Semaglutide D Dose 2, Semaglutide D Dose 3
- Where
- 3 sites in United States, Canada
- Volunteers
- 546 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Obesity
A Research Study Looking at How 50 mg Semaglutide Daily Affects Food Intake and Emptying of the Stomach in People With Obesity
This study tests if semaglutide tablets of 50 mg can help people with obesity to lower their food intake compared to placebo. This study also tests how semaglutide 50 mg works on appetite, control of eating (such as cravings and…
- Trial name
- NCT05236517
- Testing
- Semaglutide D Dose 1, Semaglutide D Dose 2, Semaglutide D Dose 3
- Where
- Germany
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes in India
The purpose of the study is to look at the change in blood sugar levels in participants with type 2 diabetes who start using oral semaglutide. Participants will get oral semaglutide as prescribed to them by the study doctor.
- Trial name
- PIONEER REAL (NCT05502562)
- Testing
- Oral semaglutide
- Volunteers
- 388 people
- Sponsor
- Novo Nordisk A/S